Can Oncolytic Viruses Make CAR-T-Cell Therapy More Adaptable in B-Cell Malignancies?
CAR-T-cell therapy is a major step forward in treating relapsed and refractory B-cell malignancies, but durable remission is limited by mechanisms the engineered T cells were not necessarily designed to overcome.
A 2026 HemaSphere article proposes an experimental way to address these problems: combining CAR-T cells with oncolytic viruses (OVs). The concept goes beyond using a virus to directly kill cancer cells. Engineered OVs could potentially modify the environment CAR-T cells operate in. The authors describe this as a transition from fixed, single-target therapy toward “polyfunctional” immunotherapy.
The idea is biologically attractive, but only two primary studies cited by the authors directly address OV-CAR-T interactions relevant to B-cell malignancies, and no clinical trial has yet evaluated an integrated OV-CAR-T strategy in these diseases.
The Limits of Single-Target CAR-T Therapy
The specificity that makes CAR-T cells effective can also create a route to resistance. CAR-T cells directed against CD19 or another single antigen apply strong selective pressure, allowing tumor cells that lose or downregulate that antigen to escape. Targeting more than one antigen can reduce this risk, but it does not address other mechanisms of CAR-T-cell failure.
B-cell malignancies develop within specialized niches in the lymph nodes, spleen, and bone marrow, where malignant cells interact with stromal cells, macrophages, regulatory T cells, and cytokine networks. CAR-T-cell failure can therefore result not only from antigen escape, but also from poor trafficking, limited persistence, T-cell exhaustion, and microenvironmental immunosuppression.
OVs could address several of these mechanisms at the same time. Instead of adding another fixed target, they could modify the tumor microenvironment, support CAR-T-cell function, and potentially broaden the immune response.
How Could Oncolytic Viruses Support CAR-T Therapy?
OVs can be engineered to preferentially infect tumor cells and carry additional therapeutic payloads. In the proposed CAR-T setting, their value comes from what happens around viral infection: tumor-cell lysis, inflammatory signaling, altered antigen presentation and recruitment or activation of immune cells.
The direct evidence in B-cell malignancies is limited but provides proof of principle. Wenthe et al. studied the oncolytic adenovirus LOAd703, engineered to express CD40L and 4-1BBL. Infection of B-cell lymphoma cells increased costimulatory and MHC molecules and was associated with stronger CAR-T-cell effector function, reduced exhaustion markers, greater chemokine secretion, improved migration and enhanced tumor killing in experimental models.
A second study used vesicular stomatitis virus and reovirus to exploit the native T-cell receptor. Viral antigens stimulated the native TCR of human CD19 CAR-T cells, promoting their expansion and improving antitumor activity. Much of the in vivo efficacy evidence, however, came from solid-tumor models, making its relevance to B-cell malignancies mechanistic.
You can also read about
Reprogramming the Tumor Microenvironment
One proposed strategy is to use OVs as local delivery systems for cytokines and chemokines. Systemic immune stimulation can be limited by toxicity, whereas viral vectors could concentrate these signals within tumor sites. Cytokine-armed OVs might support CAR-T-cell expansion and persistence, while chemokines such as CCL5, CXCL9 or CXCL10 could improve recruitment into poorly accessible disease compartments.
Strategies developed for solid tumors often focus on breaking down a dense extracellular matrix. In B-cell cancers, resistance may depend more heavily on immune-stromal signaling within marrow and lymphoid niches, so the relevant OV would need to modify cellular communication.
The same principle could apply to multiple myeloma, where malignant plasma cells depend closely on the bone marrow microenvironment. The authors propose that disrupting stromal signals or chemotactic pathways such as CXCR4 could make these niches more accessible to CAR-T cells.
Could OVs Reduce Antigen Escape?
The most interesting part of the approach may be the possibility of broadening immune pressure beyond the original CAR target. Viral oncolysis releases tumor antigens together with inflammatory signals and damage-associated molecular patterns. In principle, this could promote epitope spreading, letting endogenous T cells recognize tumor antigens other than the one targeted by the CAR.
There’s an important limitation, though. Many B-cell malignancies have relatively low tumor mutational burdens, potentially restricting the neoantigen repertoire. The authors therefore discuss engineering OVs to introduce defined antigens onto tumor cells as potentially more practical. Multipayload viral platforms could potentially combine these functions with cytokines, chemokines or checkpoint blockade.
Delivery May Be Harder in Blood Cancers Than in Solid Tumors
A major translational problem is how to deliver the virus. Intratumoral injection is feasible for accessible solid tumors but poorly suited to lymphoma involving multiple nodal sites or malignancies diffusely occupying the bone marrow.
One proposed solution is to use immune cells themselves as viral carriers. CAR-T cells could be loaded with an OV ex vivo and use their natural tumor-homing capacity to transport the virus into marrow, nodal sites, and partially shield it from neutralizing antibodies.
There is conflict, though. A virus capable of activating immunity can also impair the cell carrying it. Type I interferon generated during viral infection may promote CAR-T-cell apoptosis, exhaustion and inhibitory-receptor expression, so the therapeutic window would depend on controlling viral replication closely enough for the CAR-T cell to stay functional until delivery.
Antiviral Immunity Is Both a Barrier and a Potential Advantage
Antiviral immunity can eliminate the virus before sufficient tumor infection occurs, limiting repeated administration. Lymphodepletion with fludarabine and cyclophosphamide might temporarily suppress this response and create a more permissive window.
At the same time excessive immunosuppression could undermine one of the proposed benefits of OVs: recruitment of endogenous T cells and epitope spreading. Antiviral immune responses may themselves contribute to antitumor immunity through cross-priming of tumor-associated antigens. The ideal conditioning strategy would need to suppress premature viral clearance without eliminating the adaptive immunity a broader antitumor response depends on, a balance not yet defined experimentally.
Combining Two Immune Therapies Could Also Combine Their Toxicities
CAR-T cells and OVs can both trigger inflammatory responses, raising concern about overlapping toxicity. CAR-T-associated cytokine release syndrome involves pathways including IL-6 and IFN-γ, when OV-associated inflammation appears more interferon-dominant. How these inflammatory programs interact when both therapies are given together. There is currently no validated biomarker panel for this.
The authors propose combining viral genome measurements with serial cytokine profiling, CAR-T persistence and circulating tumor DNA. Even engineered safety switches may not fully solve the problem, since fulminant inflammatory toxicity can develop faster than some viral-ablation mechanisms can act.
How Close Is OV-CAR-T Therapy to Clinical Testing?
Not close enough to call it an emerging treatment strategy. It is more of a translational roadmap, a set of ways viral engineering might address several persistent weaknesses of CAR-T therapy at once.
Several of these ideas come from solid tumor research. Type I interferon’s effect on CAR-T cells, and how much epitope spreading actually happens in B-cell malignancies, both remain open questions. What’s needed now is more thorough testing in B-cell lymphoma models.
Even if OV-CAR-T combinations prove effective, clinical implementation would require coordinating two complex therapeutic platforms. Viral production, CAR-T manufacturing, biosafety procedures, lymphodepletion and treatment timing within the narrow clinical window of patients with aggressive disease.
You can also read about
